Resources
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 92
PxWire Volume 16, Issue 1
This issue showcases the status of access to oral PrEP with the best data available since the US foreign aid freeze disrupted PEPFAR operations. Stakeholders are digging deep to meet the moment, which includes an unprecedented opportunity to drive down HIV incidence with the rollout of lenacapavir. Lastly, our update on the HIV vaccine R&D pipeline documents an evolving and diverse portfolio of products, which remains essential for a durable end to HIV as a global health threat.
PxWire Volume 15, Issue 4
This issue provides a range of maps to help orient the field on critical HIV prevention activities: the status of delivering injectable cabotegravir; funders and countries on track for early introduction of injectable lenacapavir; and where new Phase 3 efficacy trials testing MK-8527 are taking place.
Prevention Option:
PxWire Volume 15, Issue 3
This issue of PxWire looks at the scale of shuttered prevention programs for key populations, the potential market for injectable LEN, and the devastating cuts to research for an HIV vaccine.
Prevention Option:
PxWire Volume 15, Issue 2
The field of HIV prevention is confronted with two opposing forces—programs for delivering PrEP have been shuttered all over the world by the withdrawal of the US government from global health while next-generation long-acting products have never held greater promise to accelerate HIV prevention and help the world achieve epidemic control. This issue provides a snapshot on threats to delivering PrEP, the potential of injectable lenacapavir (LEN) for PrEP, and on the implications of upstream research and development of other long-acting PrEP.
Prevention Option:
PxWire Volume 15, Issue No. 1
In this special edition of Px Wire, AVAC is going beyond a quarterly update of biomedical HIV prevention. We look at how the new US Administration’s attack on global health can be expected to devastate HIV prevention, including the capacity to deliver existing PrEP options, the scale up of new PrEP products, and the paralyzing impact on research and development.
Prevention Option:
PxWire Volume 14, Issue No. 4
In addition to an update on the PrEP pipeline, this issue of PxWire recaps the HIVR4P 2024 conference in Lima, Peru; introduces the People’s Research Agenda; and lists our Prevention Playlist, a wide range of resources to inform your decision making and action.
Prevention Option:
PxWire Volume 14, Issue No. 3
In addition to an update on the PrEP pipeline, this issue of PxWire discusses the impact of policies on PrEP uptake, contrasting Uganda’s disastrous Anti-Homosexuality Act with the positive impact of other countries’ comprehensive anti-discrimination policies.
Prevention Option:
PxWire Volume 14, Issue No. 2
The latest issue presents new research on the effectiveness of oral PrEP in cisgender women, new injectable cabotegravir approvals and rollout, and much more!
Prevention Option:
PxWire Volume 14, Issue No. 1
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Each issue includes updates, emerging issues and upcoming events.
Prevention Option:
PxWire Volume 13, Issue No. 4
As we look back on 2023, powerful cross currents confront HIV prevention and global health equity. More options than ever before could be available, but many forces threaten to undermine access to proven prevention options that exist today and the development of additional options that are still needed.
Prevention Option:
showing 1-10 of 92